Using blood markers to detect Alzheimer's disease early in Colombia
Official title: IMPLEMENTATION OF BIOFLUID MARKERS FOR EARLY DETECTION OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES IN COLOMBIA
Funded at University of Antioquia · NIH-10537769 · Data updated 2026-11-12
This study is working on finding new blood tests to help spot Alzheimer's disease and other brain disorders early, so that people in Colombia can get better care and treatment sooner.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Antioquia NIH-funded |
| Lab location | 1 site (Medellin, Colombia) |
| Project start | September 30, 2022 |
| Project end | August 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $265,000 |
| NIH project number | 1R21AG079574-01 |
| Project ID | NIH-10537769 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with a family history of Alzheimer's disease or those showing early signs of neurodegenerative conditions.
✕Less likely to help
Patients without a familial history of Alzheimer's disease or those who do not exhibit any symptoms of neurodegenerative diseases may not benefit from this research.
What this research studies
This research focuses on developing and implementing biofluid markers, specifically from blood samples, to facilitate the early detection of Alzheimer's disease and other neurodegenerative diseases in Colombia. The project aims to enhance the capabilities of the Neuroscience Group at the University of Antioquia by utilizing their extensive biobank of biological samples from familial Alzheimer's disease. By establishing the necessary infrastructure for biomarker detection, the research seeks to improve diagnosis, prevention, and treatment options for patients in the region.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate diagnoses of Alzheimer's disease, improving patient outcomes and treatment options.
How similar studies have gone: Other research has shown promise in using biofluid markers for early detection of Alzheimer's disease, indicating that this approach has potential for success.
Where this research is happening
-
University of Antioquia
Medellin, Colombia Active
Researchers
- Principal investigator: Cardona-Gómez, Gloria Patricia — University of Antioquia
- Study coordinator: Cardona-Gómez, Gloria Patricia
Related research
Other NIH-funded projects on the same topics.
-
Using biofluid markers to detect Alzheimer's disease early in Colombia
This study is looking to make it easier to spot Alzheimer's and similar brain diseases by using special markers found in blood samples, and it's designed for people in Colombia to help doctors better understand and treat these conditions.
-
Understanding resilience to Alzheimer's disease in Colombian families with genetic mutations
This study is looking at how specific genetic changes linked to early-onset Alzheimer's disease impact memory and thinking skills in people from Colombia, especially those with these mutations and their family members, to find out what helps some people stay mentally sharp despite the disease.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.